Drug intelligence / Profile preview

NTT-002

Development stage: Preclinical
Lead developer: NTT Biopharma
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

NTT-002 is a preclinical-stage drug candidate developed by NTT Biopharma for the treatment of primary and metastatic colorectal cancer. It consists of the topoisomerase I inhibitor irinotecan encapsulated within mesoporous silica nanoparticles (MSNs). This nanoparticle delivery system is designed to optimize drug loading, enhance targeted delivery to tumor cells, and improve therapeutic efficacy while minimizing the systemic toxicity typically associated with conventional irinotecan chemotherapy. By suppressing both primary tumor growth and metastatic spread, NTT-002 aims to provide a more effective treatment option for aggressive colorectal malignancies.

Other names: Irinotecan (formulated)

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on NTT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTT-002.

Explore the full profile